| Literature DB >> 28855917 |
Kohei Kazuma1, Kenji Ando1, Ken-Ichi Nihei2, Xiaoyu Wang1, Marisa Rangel3,4, Marcia Regina Franzolin5, Kanami Mori-Yasumoto6, Setsuko Sekita6, Makoto Kadowaki1, Motoyoshi Satake7, Katsuhiro Konno1.
Abstract
BACKGROUND: Among the hymenopteran insect venoms, those from social wasps and bees - such as honeybee, hornets and paper wasps - have been well documented. Their venoms are composed of a number of peptides and proteins and used for defending their nests and themselves from predators. In contrast, the venoms of solitary wasps and bees have not been the object of further research. In case of solitary bees, only major peptide components in a few venoms have been addressed. Therefore, the aim of the present study was to explore the peptide component profile of the venom from the solitary bee Xylocopa appendiculata circumvolans by peptidomic analysis with using LC-MS.Entities:
Keywords: LC-ESI-MS; Linear cationic α-helical peptide; Peptidomic analysis; Solitary bee; Venom
Year: 2017 PMID: 28855917 PMCID: PMC5575948 DOI: 10.1186/s40409-017-0130-y
Source DB: PubMed Journal: J Venom Anim Toxins Incl Trop Dis ISSN: 1678-9180
Solitary bee venom peptides
| Melectin | GFLSILKKVLPKVMAHMK-NH2 |
| Osmin | GFLSALKKYLPIVLKHV-NH2 |
| Panurgine-1 | LNWGAILKHIIK-NH2 |
| Macropin | GFGMALKLLKKVL-NH2 |
| Codesane | GMASLLAKVLPHVVKLIK-NH2 |
| HYL | GIMSSLMKKLAAHIAK-NH2 |
| Xylopin | GFVALLKKLPLILKHLH-NH2 |
| Xylopinin | GFVALLKKLPLILKHLP-NH2 |
Fig. 1LC-ESI-MS profile of crude venom extracts of Xylocopa appendiculata circumvolans. About 10% of crude venom extract of a single specimen was subjected to reverse-phase HPLC using CAPCELL PAK C18 (1.5 × 150 mm) with linear gradient of 5–65% CH3CN/H2O/0.1% formic acid over 20 min at flow rate of 200 μL/min. a UV absorption by PDA. b Total ion current (TIC). Numbers in B show “virtual” fraction number as in Tables 2 to 6
Mass fingerprint of crude venom from X. appendiculata circumvolans
| Fraction no. | Retention time (min) | [M + H]+
|
|---|---|---|
| 1 | 1.0–1.5 | 116.071, 175.119, 184.073, 348.071, 381.080, 405.236, 441.101 |
| 2 | 1.5–2.0 | 132.102, 268.104, 322.077, 377.058, 733.323, 759.499 |
| 3 | 2.0–3.0 | 284.099, 373.281, 437.051, 469.277, 654.357, 817.504, 947.484, 1002.508 |
| 4 | 3.0–4.2 | 182.117, 431.214, 598.428, 937.390, 1368.747 |
| 5 | 4.2–5.0 | 623.423, 646.423, 1517.714, 2064.031 |
| 6 | 5.0–6.0 | 930.588, 969.653, 1165.500, 1189.459, 1338.913, 1306.915, 1715.808, 2807.314 |
| 7 | 6.0–6.4 | 322.176, 393.214, 961.656, 1210.815, 1451.994, 1925.941 |
| 8 | 6.4–7.0 | 714.306, 1211.799, 1268.821, 1336.563, 1510.001, 3225.624, 3243.642 |
| 9 | 7.0–8.0 | 637.346, 715.291, 793.482, 838.421, 875.527, 1082.720, 1178.861, 1337.549, 1565.078, 1636.116, 2064.036, 3400.643 |
| 10 | 8.0–9.0 | 690.456, 747.477, 908.509, 933.515, 937.678, 1249.897, 1427.606, 1608.000, 1626.012, 1694.121, 2065.019, 3187.725, 3245.730 |
| 11 | 9.0–10.0 | 379.114, 506.298, 696.502, 761.492, 988.656, 1021.593, 1085.709, 1366.821, 1384.832, 1882.253, 3187.723, 3245.728 |
| 12 | 10.0–10.8 | 370.199, 941.598, 1690.115, 1735.185, 1939.274 |
| 13 | 10.8–11.4 | 619.381, 926.118, 1553.055, 1783.363, 1997.276 |
| 14 | 11.4–12.0 | 1311.877, 1803.199, 1899.267, 2087.312, 2139.353, 2236.641, 3087.760, 3256.821 |
| 15 | 12.0–12.7 | 680.314, 704.272, 1424.961, 1956.252, 2121.345, 2197.359, 2281.379, 2648.565 |
| 16 | 12.7–13.2 | 2095.280, 2113.292 |
| 17 | 13.2–13.6 | 662.303, 1316.450, 2077.267, 2153.287, 2171.297 |
| 18 | 13.6–15.0 | 1709.063, 3860.509, 4015.525 |
Unknown peptides
| Fraction no. | [M + H]+ | Sequence |
|---|---|---|
| 3 | 469.277 | HVLT |
| 3 | 654.357 | EVLSAH-NH2 |
| 4 | 431.214 | SVEP |
| 3 | 947.484 | EMKSVEPK |
| 9 | 637.346 | FAFPR |
| 9 | 838.421 | SNFAFPR |
| 5 | 646.413 | LVSSLK |
| 9 | 793.482 | FLVSSLK |
| 10 | 908.509 | DFLVSSLK |
| 11 | 1021.593 | LDFLVSSLK |
| 4 | 937.390 | EYEPEDR |
| 6 | 1165.500 | LDEYEPEDR |
| 8 | 1336.563 | NGLDEYEPEDR |
| 9 | 1337.549 | DGLDEYEPEDR |
Peptide sequences analyzed from MS/MS spectra
| Fraction no. | [M + H]+ | Sequence | Fraction no. | [M + H]+ | Sequence |
|---|---|---|---|---|---|
| 1 | 405.236 | HLH-NH2 | 9 | 637.346 | FAFPR |
| 793.482 | FLVSSLK | ||||
| 838.421 | SNFAFPR | ||||
| 875.527 | GFVALLKK | ||||
| 1082.720 | LPLILKHLH-NH2 | ||||
| 1178.861 | LLKKLPLILK | ||||
| 1337.549 | DGLDEYEPEDR | ||||
| 1565.078 | LLKKLPLILKHLH-NH2 | ||||
| 1636.116 | ALLKKLPLILKHLH-NH2 | ||||
| 2 | 759.499 | ILKHLH-NH2 | 10 | 690.456 | FVALLK |
| 747.477 | GFVLKK | ||||
| 908.509 | DFLVSSLK | ||||
| 937.678 | LKKLPLIL | ||||
| 1249.897 | ALLKKLPLILK | ||||
| 1694.121 | ALLKKLPLILKHLHG | ||||
| 3 | 373.281 | ILK | 11 | 506.298 | GFVAL |
| 469.277 | HVLT | 696.502 | PLKLI | ||
| 817.504 | ILKHLHG | 988.656 | GFVALLKKL | ||
| 947.489 | EMKSVEPK | 1021.593 | LDFLVSSLK | ||
| 1085.709 | GFVALLKKLP | ||||
| 1882.253 | FVALLKKLPLILKH | ||||
| 4 | 431.214 | SVEP | 12 | 1690.115 | GFVALLKKLPLILKH |
| 598.428 | LKKLP | 1735.185 | VALLKKLPLILKHLH-NH2 | ||
| 937.390 | EYEPEDR | 1939.274 | GFVALLKKLPLILKHLH-NH2 | ||
| 5 | 623.423 | LILKH | 13 | 619.381 | GFVALL |
| 646.413 | LVSSLK | 1553.055 | GFVALLKKLPLILK | ||
| 1997.276 | GFVALLKKLPLILKHLKG | ||||
| 6 | 930.588 | LILKHLHG | 14 | 1311.877 | GFVALLKKLPLI |
| 969.653 | PLILKHLH-NH2 | 1803.199 | GFVALLKKLPLILKHL | ||
| 1165.500 | LDEYEPEDR | 1899.267 | GFVALLKKLPLILKHLP-NH2 | ||
| 1338.913 | KKLPLILKHLH-NH2 | 2139.353 | EAGFVALLKKLPLILKHLH-NH2 | ||
| 1396.915 | KKLPLILKHLHG | ||||
| 7 | 322.176 | GFV | 15 | 1424.961 | GFVALLKKLPLIL |
| 393.214 | GFVA | ||||
| 961.656 | KLPLILKH | ||||
| 1210.815 | KLPLILKHLH-NH2 | ||||
| 1451.994 | LKKLPLILKHLH-NH2 | ||||
| 8 | 1211.799 | KLPLILIKHLH | |||
| 1268.821 | KLPLILKHLHG | ||||
| 1336.563 | NGLDEYEPEDR | ||||
| 1500.001 | LKKLPLILKHLHG |
Peptides related to xylopin
| Fraction no. | [M + H]+ | Sequence |
|---|---|---|
| 7 | 322.176 | GFV |
| 7 | 393.214 | GFVA |
| 11 | 506.502 | GFVAL |
| 13 | 619.381 | GFVALL |
| 10 | 747.477 | GFVALLK |
| 9 | 875.527 | GFVALLKK |
| 11 | 988.656 | GFVALLKKL |
| 11 | 1085.709 | GFVALLKKLP |
| 14 | 1311.877 | GFVALLKKLPLI |
| 15 | 1424.961 | GFVALLKKLPLIL |
| 13 | 1553.055 | GFVALLKKLPLILK |
| 12 | 1690.115 | GFVALLKKLPLILKH |
| 14 | 1803.199 | GFVALLKKLPLILKHL |
| 3 | 373.281 | ILK |
| 5 | 623.423 | LILKH |
| 7 | 961.656 | KLPLILKH |
| 8 | 1211.799 | KLPLILKHLH |
| 9 | 1178.861 | LLKKLPLILK |
| 10 | 690.456 | FVALLK |
| 10 | 1249.897 | ALLKKLPLILK |
| 10 | 937.678 | LKKLPLILK |
| 11 | 696.502 | LPLILK |
| 1 | 405.236 | HLH-NH2 |
| 2 | 759.499 | ILKHLH-NH2 |
| 6 | 969.653 | PLILKHLH-NH2 |
| 9 | 1082.720 | LPLILKHLH-NH2 |
| 7 | 1210.815 | KLPLILKHLH-NH2 |
| 6 | 1338.913 | KKLPLILKHLH-NH2 |
| 7 | 1451.994 | LKKLPLILKHLH-NH2 |
| 9 | 1565.078 | LLKKLPLILKHLH-NH2 |
| 9 | 1636.116 | ALLKKLPLILKHLH-NH2 |
| 12 | 1735.185 | VALLKKLPLILKHLH-NH2 |
| 11 | 1882.253 | FVALLKKLPLILKHLH-NH2 |
| 14 | 1899.267 | GFVALLKKLPLILKHLP-NH2 a |
| 12 | 1939.274 | GFVALLKKLPLILKHLH-NH2 b |
| 19 | 2139.353 | EAGFVALLKKLPLILKHLH-NH2 |
aXylopinin, bxylopin
Peptides without amidated C-terminus
| Fraction no. | [M + H] | Sequence |
|---|---|---|
| 3 | 817.504 | ILKHLHG |
| 6 | 930.588 | LILKHLHG |
| 8 | 1268.821 | KLPLILKHLHG |
| 6 | 1396.915 | KKLPLILKHLHG |
| 8 | 1510.001 | LKKLPLILKHLHG |
| 10 | 1694.121 | ALLKKLPLILKHLHG |
| 13 | 1997.276 | GFVALLKKLPLILKHLHG |
Fig. 2Fractionation of venom extracts of Xylocopa appendiculata circumvolans by reverse-phase HPLC using CAPCELL PAK C18 (6 × 150 mm) with linear gradient of 5–65% CH3CN/H2O/0.1% TFA over 30 min at flow rate of 1 mL/min. UV absorption was monitored at 215 nm
Fig. 3Helical wheel projection of the sequence of xylopin and xylopinin. In this view through the helix axis, the hydrophilic His (H) and Lys (K) residues are located on one side and the hydrophobic Ala (A), Phe (F), Ile (I) and Leu (L) residues on the other side of the helix
Fig. 4The degranulation in RBL-2H3 cells (a mucosal-type mast cell model) measured by the β-hexosaminidase release, basal and after treatment with xylopin, the novel venom peptide from the solitary bee Xylocopa appendiculata circumvolans. Concentrations are in μM and data represent the mean from two to four independent experiments
Minimum inhibitory concentration (MIC) of xylopin
| Microorganism | MIC (μM) |
|---|---|
| Gram-positive | |
|
| 15.0 |
|
| 1.9 |
|
| 3.75 |
|
| 3.75 |
|
| 3.75 |
|
| 15.0 |
| Gram-negative | |
|
| 3.75 |
|
| 7.5 |
|
| 3.75 |
|
| 3.75 |
|
| 7.5 |
|
| 7.5 |
|
| 7.5 |
|
| >30 |
|
| 30 |
|
| 3.75 |
| Yeast | |
|
| 7.5 |
|
| 3.75 |
Fig. 5Representative recordings of single channel incorporation in asolectin artificial lipid bilayers induced by xylopin at 1 μM concentration. a Vhold = + 140 mV, pore conductances = 63 and 105 pS. b Vhold = −140 mV, pore conductance = 143 and 259 pS. c Vhold was set at +100 mV for 5 s and was switched to −100 mV for the remaining 5 s, pore conductance = 175 pS. Solutions: a and b 150 mM KCl, and c 500 mM KCl (symmetrical). Arrows indicate channel apertures or closings. Four independent experiments were performed